Back to Search
Start Over
Fatal cardiac and renal allograft rejection with lenalidomide therapy for light-chain amyloidosis.
- Source :
-
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [Am J Transplant] 2013 Oct; Vol. 13 (10), pp. 2730-3. Date of Electronic Publication: 2013 Aug 05. - Publication Year :
- 2013
-
Abstract
- We describe a patient who underwent a successful heart and kidney transplant for light-chain amyloidosis. She had an excellent hematologic response to bortezomib/dexamethasone therapy. Follow-up therapy with lenalidomide was started, and the patient quickly had a fatal allograft rejection of the heart and kidney. We present evidence to support the theory that lenalidomide, a known immunomodulator, may have stimulated the immune system and precipitated the fatal rejection episode.<br /> (© Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Subjects :
- Aged
Allografts
Amyloidosis metabolism
Combined Modality Therapy
Female
Graft Rejection mortality
Heart Diseases drug therapy
Humans
Immunoglobulin Light Chains metabolism
Kidney Diseases drug therapy
Lenalidomide
Prognosis
Thalidomide adverse effects
Amyloidosis drug therapy
Graft Rejection chemically induced
Heart Transplantation
Immunologic Factors adverse effects
Kidney Transplantation
Thalidomide analogs & derivatives
Subjects
Details
- Language :
- English
- ISSN :
- 1600-6143
- Volume :
- 13
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
- Publication Type :
- Academic Journal
- Accession number :
- 23914832
- Full Text :
- https://doi.org/10.1111/ajt.12391